355 related articles for article (PubMed ID: 17045309)
1. Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein.
Baltes S; Gastens AM; Fedrowitz M; Potschka H; Kaever V; Löscher W
Neuropharmacology; 2007 Feb; 52(2):333-46. PubMed ID: 17045309
[TBL] [Abstract][Full Text] [Related]
2. The antiepileptic drug lamotrigine is a substrate of mouse and human breast cancer resistance protein (ABCG2).
Römermann K; Helmer R; Löscher W
Neuropharmacology; 2015 Jun; 93():7-14. PubMed ID: 25645391
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of transport of common antiepileptic drugs by human multidrug resistance-associated proteins (MRP1, 2 and 5) that are overexpressed in pharmacoresistant epilepsy.
Luna-Tortós C; Fedrowitz M; Löscher W
Neuropharmacology; 2010 Jun; 58(7):1019-32. PubMed ID: 20080116
[TBL] [Abstract][Full Text] [Related]
4. Several major antiepileptic drugs are substrates for human P-glycoprotein.
Luna-Tortós C; Fedrowitz M; Löscher W
Neuropharmacology; 2008 Dec; 55(8):1364-75. PubMed ID: 18824002
[TBL] [Abstract][Full Text] [Related]
5. Valproic acid is not a substrate for P-glycoprotein or multidrug resistance proteins 1 and 2 in a number of in vitro and in vivo transport assays.
Baltes S; Fedrowitz M; Tortós CL; Potschka H; Löscher W
J Pharmacol Exp Ther; 2007 Jan; 320(1):331-43. PubMed ID: 17043155
[TBL] [Abstract][Full Text] [Related]
6. Do ATP-binding cassette transporters cause pharmacoresistance in epilepsy? Problems and approaches in determining which antiepileptic drugs are affected.
Löscher W; Luna-Tortós C; Römermann K; Fedrowitz M
Curr Pharm Des; 2011; 17(26):2808-28. PubMed ID: 21827408
[TBL] [Abstract][Full Text] [Related]
7. Upregulation of brain expression of P-glycoprotein in MRP2-deficient TR(-) rats resembles seizure-induced up-regulation of this drug efflux transporter in normal rats.
Hoffmann K; Löscher W
Epilepsia; 2007 Apr; 48(4):631-45. PubMed ID: 17437408
[TBL] [Abstract][Full Text] [Related]
8. Potential role for human P-glycoprotein in the transport of lacosamide.
Zhang C; Chanteux H; Zuo Z; Kwan P; Baum L
Epilepsia; 2013 Jul; 54(7):1154-60. PubMed ID: 23551115
[TBL] [Abstract][Full Text] [Related]
9. In vitro transport profile of carbamazepine, oxcarbazepine, eslicarbazepine acetate, and their active metabolites by human P-glycoprotein.
Zhang C; Zuo Z; Kwan P; Baum L
Epilepsia; 2011 Oct; 52(10):1894-904. PubMed ID: 21692796
[TBL] [Abstract][Full Text] [Related]
10. Development and characterization of LLC-PK1 cells containing Sprague-Dawley rat Abcb1a (Mdr1a): comparison of rat P-glycoprotein transport to human and mouse.
Booth-Genthe CL; Louie SW; Carlini EJ; Li B; Leake BF; Eisenhandler R; Hochman JH; Mei Q; Kim RB; Rushmore TH; Yamazaki M
J Pharmacol Toxicol Methods; 2006; 54(1):78-89. PubMed ID: 16545584
[TBL] [Abstract][Full Text] [Related]
11. Establishment and characterization of the transformants stably-expressing MDR1 derived from various animal species in LLC-PK1.
Takeuchi T; Yoshitomi S; Higuchi T; Ikemoto K; Niwa S; Ebihara T; Katoh M; Yokoi T; Asahi S
Pharm Res; 2006 Jul; 23(7):1460-72. PubMed ID: 16779700
[TBL] [Abstract][Full Text] [Related]
12. In vitro concentration dependent transport of phenytoin and phenobarbital, but not ethosuximide, by human P-glycoprotein.
Zhang C; Kwan P; Zuo Z; Baum L
Life Sci; 2010 Jun; 86(23-24):899-905. PubMed ID: 20417647
[TBL] [Abstract][Full Text] [Related]
13. Differences in the expression of endogenous efflux transporters in MDR1-transfected versus wildtype cell lines affect P-glycoprotein mediated drug transport.
Kuteykin-Teplyakov K; Luna-Tortós C; Ambroziak K; Löscher W
Br J Pharmacol; 2010 Jul; 160(6):1453-63. PubMed ID: 20590635
[TBL] [Abstract][Full Text] [Related]
14. The antiepileptic drug topiramate is a substrate for human P-glycoprotein but not multidrug resistance proteins.
Luna-Tortós C; Rambeck B; Jürgens UH; Löscher W
Pharm Res; 2009 Nov; 26(11):2464-70. PubMed ID: 19730994
[TBL] [Abstract][Full Text] [Related]
15. In vitro transport assays of rufinamide, pregabalin, and zonisamide by human P-glycoprotein.
Chan PS; Zhang C; Zuo Z; Kwan P; Baum L
Epilepsy Res; 2014 Mar; 108(3):359-66. PubMed ID: 24530088
[TBL] [Abstract][Full Text] [Related]
16. Knockout of P-glycoprotein does not alter antiepileptic drug efficacy in the intrahippocampal kainate model of mesial temporal lobe epilepsy in mice.
Bankstahl M; Klein S; Römermann K; Löscher W
Neuropharmacology; 2016 Oct; 109():183-195. PubMed ID: 27288003
[TBL] [Abstract][Full Text] [Related]
17. Interplay between MRP inhibition and metabolism of MRP inhibitors: the case of curcumin.
Wortelboer HM; Usta M; van der Velde AE; Boersma MG; Spenkelink B; van Zanden JJ; Rietjens IM; van Bladeren PJ; Cnubben NH
Chem Res Toxicol; 2003 Dec; 16(12):1642-51. PubMed ID: 14680379
[TBL] [Abstract][Full Text] [Related]
18. Kinetic analyses for species differences in P-glycoprotein-mediated drug transport.
Katoh M; Suzuyama N; Takeuchi T; Yoshitomi S; Asahi S; Yokoi T
J Pharm Sci; 2006 Dec; 95(12):2673-83. PubMed ID: 16892207
[TBL] [Abstract][Full Text] [Related]
19. Lack of interactions between breast cancer resistance protein (bcrp/abcg2) and selected antiepileptic agents.
Cerveny L; Pavek P; Malakova J; Staud F; Fendrich Z
Epilepsia; 2006 Mar; 47(3):461-8. PubMed ID: 16529607
[TBL] [Abstract][Full Text] [Related]
20. The role of P-glycoprotein in intestinal transport versus the BBB transport of tetraphenylphosphonium.
Swed A; Eyal S; Madar I; Zohar-Kontante H; Weiss L; Hoffman A
Mol Pharm; 2009; 6(6):1883-90. PubMed ID: 19722701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
